- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02549742
Electrochemotherapy on Head and Neck Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Electric pulses may be used to transiently permeabilise cell membranes, enabling passage of otherwise non-permeating molecules. This dramatically enhances the cytotoxic effect of certain chemotherapeutic agents, and is termed electrochemotherapy. Electrochemotherapy is now standardly used in the treatment of cutaneous metastases of various cancers in over 100 cancer centers around Europe.
The intention of this trial is to investigate the possible use of electrochemotherapy in recurrent head and neck cancer as a palliative treatment. Surgery and radiotherapy, with the possible addition of chemotherapy, cures a large part of patients with head and neck cancer. However, in the event of recurrence curative options may be exhausted and the patient is referred for palliative chemotherapy.
It is for this patient group, the investigators propose electrochemotherapy in a clinical trial.
The electrochemotherapy is administered as a once-only treatment, with possible retreatment after eight weeks. Under general anesthesia, chemotherapy is administered intravenously, followed by application of electric pulses to the tumour area. Before treatment, the location and spread of the tumour is determined by imaging.
The trial includes evaluation of response by MRI (magnetic resonance imaging) and PET/CT (Positron Emission Tomography - Computed Tomography) scans (base-line, 4 weeks, 8 weeks), tissue samples, as well as adverse events registration and questionnaires on quality of life. The planned study is a phase II clinical study, prospective, observational with up to 25 patients.
Treatments will be performed in collaboration between the Department of Oncology, Copenhagen University Hospital Herlev, which has extensive experience in electrochemotherapy, and the Department of Ear Nose and Throat Surgery at Copenhagen University Hospital Rigshospitalet, that has the surgical expertise and set-up needed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Christina C. Plaschke, MD
- Phone Number: +45 29 25 92 45
- Email: caroline@dadlnet.dk
Study Contact Backup
- Name: Irene Wessel, MD
- Phone Number: +45 35 45 83 22
- Email: irene.wessel.01@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- Department of Otorhinolaryngology, Rigshospitalet, Copenhagen University Hospital
-
Contact:
- Christina C. Plaschke, MD
- Phone Number: +45 29 25 92 45
- Email: caroline@dadlnet.dk
-
Contact:
- Irene Wessel, MD
- Phone Number: +45 35 45 83 22
- Email: irene.wessel.01@regionh.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject age > 18 years.
- Verified cancer of the head and neck area of any histology.
- At least one tumour lesion should be accessible for electroporation.
- Performance status WHO <= 2nd
- Progressive and / or metastatic disease.
- Expected survival of > 3 months.
- Measurable disease is defined as at least one measurable lesion by RECIST 1.1.
- A treatment-free interval of more than 4 weeks since chemotherapy or radiation therapy.
- The participant should have been offered the current standard treatment. If there are no further standard treatment to offer or if the participant does not want to receive this, the participant may be included in the trial.
- The participant should be able to understand the information for participants and be willing and able to comply with hospitalization in the treatment and the agreed follow-up visits and tests.
- Platelets ≥ 50 billion / L, INR (international normalized ratio) > 1.5. Medical correction is permitted, e.g. correction using vitamin K.
- Sexually active women who can become pregnant should use adequate contraception during this trial and 6 months after administration of bleomycin (pill, spiral, injection of prolonged progestin subdermal implantation, hormone-containing vaginal devices, transdermal patches).
- Signed informed consent. -
Exclusion Criteria:
Participants should be excluded if they meet just one of the criteria stated below.
- Symptomatic progression of the participants cancerous disease that requires another intervention.
- Acute lung infection
- Symptoms of lung function impairment. This triggers a lung function test (DLCO = diffusing capacity of the lungs for carbon monoxide), if moderate to severe the participant will be excluded.
- Previous bleomycin treatment with cumulative dose more than 240,000 Units / m2.
- History of severe allergic reactions associated with bleomycin.
- Allergy to constituents of the planned anesthetic.
- Coagulation disorder which can not be corrected.
- Chronic renal dysfunction with creatinine> 150 micromoles / liter, will trigger a Cr-51-EDTA (Chromium-51-ethylenediamine tetra acetic acid) clearance. If this is too impaired, the participant is excluded.
- Pregnancy or lactation.
- While participation in other clinical trials involving experimental drugs or involved in a trial within 4 weeks prior to study drug administration.
- Other disorders investigator finds incompatible with participation in the trial. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Electrochemotherapy
25 patients treated with electrochemotherapy
|
Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
Other Names:
Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
Administered intravenously or injected into the tumour before electroporation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tumour response from PET/CT scans (Positron Emission Tomography - Computed Tomography)
Time Frame: 8 weeks after treatment
|
8 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumour response from MRI scans (Magnetic resonance imaging)
Time Frame: 8 weeks after treatment
|
8 weeks after treatment
|
|
Tumour response from tissue samples
Time Frame: 4 weeks after treatment
|
Still cancer activity or not
|
4 weeks after treatment
|
VAS score (Visual Analogue Scale)
Time Frame: baseline, 4 weeks and 8 weeks after treatment
|
Participant assessed
|
baseline, 4 weeks and 8 weeks after treatment
|
Quality of life
Time Frame: baseline, 4 weeks and 8 weeks after treatment
|
EORTC scores for head and neck (The European Organisation for Research and Treatment of Cancer)
|
baseline, 4 weeks and 8 weeks after treatment
|
CTCAE recordings (Common Terminology Criteria for Adverse Events)
Time Frame: baseline, 4 weeks and 8 weeks after treatment
|
side effects scored by CTCAE version 4.0
|
baseline, 4 weeks and 8 weeks after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Julie Gehl, MD, Denmark: Herlev and Gentofte Hospital, University of Copenhagen
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HH1222
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on Electrochemotherapy
-
IGEATerminatedColorectal Adenocarcinoma
-
Uppsala University HospitalWithdrawnBreast Cancer | Skin MetastasesSweden
-
University Women's Hospital TübingenCompleted
-
Universita di VeronaIGEATerminatedPancreatic CancerItaly
-
Copenhagen University Hospital at HerlevWithdrawnUlcerated Cutaneous MetastasesDenmark
-
Institute of Oncology LjubljanaRecruiting
-
Copenhagen University Hospital at HerlevTerminated
-
European Institute of OncologyMerck Sharp & Dohme LLCRecruiting
-
Sophie HorbachIGEAUnknownVascular Malformations | Capillary MalformationsNetherlands
-
Institute of Oncology LjubljanaUniversity Medical Centre LjubljanaCompleted